PSMD14
ENSG00000115233
Target class
Enzyme
Chromosome
2
Approved drugs
3
Clinical candidates (approved and in development)
5
- Approved drugs
- 3
- Clinical candidates (approved and in development)
- 5
- Chemical probe available
- Yes
- Target name
- PSMD14
- Gene name
- Proteasome 26S subunit, non-ATPase 14
- Gene symbol
- PSMD14
- Protein name
- Ubiquitin C-terminal hydrolase PSMD14 (EC 3.4.19.12) (26S proteasome non-ATPase regulatory subunit 14) (26S proteasome regulatory subunit RPN11) (26S proteasome-associated PAD1 homolog 1)
- POH1
- pad1
- Rpn11
- Gene biotype
- Protein coding
- Gene family
- Proteasome|JAMM/MPN+ metallopeptidase family
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 127.64
- Tissue specificity (Gini)
- 0.211
- Tissue specificity (tau)
- 0.712
- KEGG gene identifiers
- hsa:10213
- Protein interaction confidence
- 0.886026
- Protein interaction partners
- 115
- R-HSA-1169091
- R-HSA-1234176
- R-HSA-1236974
- R-HSA-1236978
- R-HSA-174084
- R-HSA-174113
- R-HSA-174154
- R-HSA-174178
- R-HSA-174184
- R-HSA-180534
- R-HSA-180585
- R-HSA-187577
- R-HSA-195253
- R-HSA-202424
- R-HSA-211733
- R-HSA-2467813
- R-HSA-2871837
- R-HSA-349425
- R-HSA-350562
- R-HSA-382556
- R-HSA-450408
- R-HSA-4608870
- R-HSA-4641257
- R-HSA-4641258
- R-HSA-5358346
And 44 more, listed on the interactive page.
- End position
- 161411720
- Start position
- 161308414
- Chromosome
- 2
- Strand
- Forward
- Nucleoplasm
- Tissue specificity (tau)
- 0.712306
- Expression inequality (Gini)
- 0.210552
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 127.64
- Cells - Cultured fibroblasts
- 94.29
- Muscle - Skeletal
- 64.7
- Brain - Cerebellar Hemisphere
- 56.26
- Brain - Frontal Cortex (BA9)
- 53.85
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes127.64
- Cells - Cultured fibroblasts94.29
- Muscle - Skeletal64.7
- Brain - Cerebellar Hemisphere56.26
- Brain - Frontal Cortex (BA9)53.85
- Brain - Spinal cord (cervical c-1)52.35
- Esophagus - Mucosa52.21
- Testis49.81
- Adrenal Gland49.52
- Brain - Cerebellum44.61
- Artery - Tibial43.04
- Artery - Coronary42.97
- Pituitary42.76
- Brain - Hypothalamus42.68
- Skin - Sun Exposed (Lower leg)42.21
- Skin - Not Sun Exposed (Suprapubic)42.07
- Artery - Aorta41.1
- Adipose - Subcutaneous39.04
- Uterus38.12
- Vagina38.03
- Thyroid37.96
- Brain - Cortex37.93
- Nerve - Tibial37.66
- Brain - Nucleus accumbens (basal ganglia)37.13
- Lung36.99
And 29 more, listed on the interactive page.
- GO:0000724
- GO:0006303
- GO:0006511
- GO:0006890
- GO:0016241
- GO:0016579
- GO:0061136
- GO:0070536
- GO:0000502
- GO:0005576
- GO:0005634
- GO:0005654
- GO:0005829
- GO:0008541
- GO:0034774
- GO:1904813
- GO:0004843
- GO:0005515
- GO:0008237
- GO:0061133
- GO:0061578
- GO:0070628
- GO:0140492
Related records
Trials (789)
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- 3D PET Myocardial Blood Flow and Rb82 Infusion Profiles
- 4SCAR-T Therapy Post CD19-targeted Immunotherapy
- A Basket Study of CTA313 in Participants With Active Autoimmune Diseases
- A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors
- A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment
- A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer
- A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus
- A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors
- A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer
- A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
- A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion
- A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer
- A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."
- A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II
- A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy
Drugs (5)
- Bortezomib D-mannitol 26S proteasome inhibitor
- Carfilzomib 26S proteasome inhibitor
- Ixazomib 26S proteasome inhibitor
- Ixazomib citrate 26S proteasome inhibitor
- Oprozomib 26S proteasome inhibitor